Lakewood Health System uses new scanner to diagnose diseases

Bozz District

STAPLES — Lakewood Health System recently introduced a new detection and diagnostic service to patients and physicians in conjunction with Shared Medical Services of Cottage Grove, Wisconsin. The PET-CT scanner is now being used to help diagnose cancer and other diseases. The scanner provides great sensitivity in detecting and locating […]

STAPLES — Lakewood Health System recently introduced a new detection and diagnostic service to patients and physicians in conjunction with Shared Medical Services of Cottage Grove, Wisconsin.

The PET-CT scanner is now being used to help diagnose cancer and other diseases. The scanner provides great sensitivity in detecting and locating abnormalities in tissue throughout the body, according to a news release, and became available Wednesday, July 21, by Lakewood.

PET, or positron emission tomography, uses radioactive glucose to image the body’s metabolism at the cellular level, mapping the chemical functioning of organs or tissue.

Since cancer cells use more glucose than other cells in the body, PET can reveal the presence of cancerous tumors and provide information about whether cancer has spread, a key component of cancer treatment.

PET can also be used to diagnose heart disease and brain disorders, like epilepsy, Alzheimer’s and Parkinson’s. CT, or computed tomography, is used to image a patient’s anatomy and can reveal abnormalities.

Newsletter signup for email alerts

Used together in one machine, PET-CT combines PET’s early detection of disease with the precise internal organ visualization of CT. The PET-CT procedure is painless and noninvasive and usually takes about half an hour.

“It will enhance the care and services at Lakewood, so we can provide the best diagnosis and treatment options to our patients,” Dr. Christine Albrecht, Lakewood chief medical officer, stated in the release.

Next Post

Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

Arvinas ARVN announced that it has entered into a global collaboration with Pfizer PFE to co-develop and co-commercialize its investigational breast cancer therapy candidate, ARV-471. Shares increased 8.97% following the announcement, as investors cheered the collaboration given Pfizer’s expertise in the targeted space. The candidate is an oral PROTAC (PROteolysis […]